A phase 2 study of vemurafenib in a variety of BRAF p.V600 mutation‐positive non‐melanoma cancers showed partial response in 1 patient with SDC.40 Additionally, a recent report describes a patient who presented with widely metastatic disease and achieved an excellent response to combination chemotherapy with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor).41 Clearly, routine testing for BRAF mutations in SDC seems warranted to select patients for targeted therapy. The gene discussed is MAP2K7; the disease is melanoma.